Welcome to our dedicated page for BNB Plus news (Ticker: BNBX), a resource for investors and traders seeking the latest updates and insights on BNB Plus stock.
BNB Plus Corp. (BNBX) generates news across both digital asset and biotechnology domains. As a Nasdaq-listed company that combines a BNB-focused digital asset treasury with nucleic acid production activities, its announcements cover developments in its BNB strategy as well as operational milestones for its LineaDNA platform.
On the digital asset side, BNB Plus issues updates on its BNB treasury holdings, private placements that support its yield-focused strategy, and tools such as the BNBX.io dashboard, which it describes as providing real-time portfolio and company metrics. These disclosures outline how the company is implementing what it calls a transparent, actively managed BNB treasury that blends DeFi and Binance-native yield opportunities.
In biotechnology and diagnostics, the company reports on LineaDNA production and customer activity through its LineaRx subsidiary. Recent news items include record LineaDNA shipments, multi-gram deliveries under supply agreements, and accelerated multi-year orders from customers in the in vitro diagnostics and biotherapeutic markets. These updates highlight the role of LineaDNA as a cell-free DNA platform used in applications such as cancer diagnostic tests.
Corporate and governance developments also feature in BNB Plus news, including its rebranding from Applied DNA Sciences, changes in board leadership, and shareholder approvals related to capital structure and warrant exercisability. Investors and observers can use this news stream to follow how the company advances its dual mandate in BNB-based treasury management and nucleic acid production.
For those tracking BNB Plus, the news page provides a centralized view of treasury updates, financing transactions, LineaDNA orders and shipments, and key corporate actions that the company discloses through press releases.
Applied DNA Sciences (NASDAQ: BNBX) launched BNBX.io, a real-time dashboard showing the company’s BNB treasury holdings, valuation metrics, and capitalization details.
Corporate update as of Oct 27, 2025: 4.35M shares outstanding, 23.71M fully diluted shares, ~15,553 BNB held via direct holdings and OBNB Trust units, and $8.4M cash. The company recently closed a private placement of up to $58M to support a yield-focused BNB treasury strategy and plans a weekly BNB newsletter plus additional dashboard features.
Applied DNA Sciences (NASDAQ: BNBX) closed a private placement (PIPE) on October 22, 2025, generating approximately $27.0 million gross proceeds with the potential for up to an additional $31 million from future warrant exercises. Gross proceeds included $15.3 million in cash and stablecoins and $11.71 million in OBNB trust units.
The company received 435,638 trust units representing underlying ownership of 10,647 BNB tokens and separately purchased an additional 4,908 BNB tokens (~$5.3M as of Oct 20, 2025). Prefunded warrants and related warrants are not exercisable until stockholder approval. Applied DNA also reported streamlining actions yielding approximately $2.9M in annualized cost savings and intends to use proceeds to implement its BNB treasury strategy and support working capital.